Table 2b.
Age | Sex | BMI | ASA grade | T stage | N stage | Differentiation | Venous invasion | Margin involvement | Peritoneal involvement | Tumour perforation | Adjuvant therapy | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NLR | 0.009 | 0.398 | <0.001 | 0.156 | 0.069 | 0.287 | 0.018 | 0.002 | 0.219 | 0.195 | <0.001 | 0.063 |
NLS | 0.002 | 0.746 | 0.003 | 0.880 | 0.039 | 0.504 | 0.073 | 0.078 | 0.069 | 0.062 | 0.004 | 0.301 |
PLR | <0.001 | 0.391 | <0.001 | 0.294 | 0.001 | 0.395 | 0.087 | 0.214 | 0.095 | 0.002 | 0.803 | 0.758 |
PLS | 0.008 | 0.827 | <0.001 | 0.337 | 0.001 | 0.449 | 0.029 | 0.002 | 0.012 | 0.005 | 0.043 | 0.907 |
LMR | <0.001 | 0.004 | 0.030 | 0.705 | 0.063 | 0.948 | 0.557 | 0.133 | 0.750 | 0.085 | 0.041 | 0.067 |
LMS | <0.001 | 0.872 | 0.165 | 0.841 | 0.001 | 0.412 | 0.044 | 0.158 | 0.033 | <0.001 | 0.184 | 0.097 |
NPS | 0.649 | 0.990 | 0.016 | 0.753 | 0.004 | 0.017 | 0.005 | 0.013 | 0.015 | 0.277 | 0.375 | 0.341 |
CAR | 0.008 | 0.618 | 0.027 | 0.009 | <0.001 | 0.071 | 0.001 | 0.011 | 0.037 | 0.007 | 0.004 | 0.341 |
mGPS | 0.180 | 0.913 | <0.001 | 0.294 | <0.001 | 0.616 | <0.001 | 0.006 | 0.005 | 0.003 | 0.001 | 0.422 |
*p <0.01 is considered significant.
NLR neutrophil–lymphocyte ratio, NLS neutrophil–lymphocyte score, CAR C-reactive protein albumin ratio, mGPS modified Glasgow prognostic score, NPS neutrophil–platelet score, LMS lymphocyte–monocyte score, LMR lymphocyte–monocyte ratio, PLR platelet–lymphocyte ratio, PLS platelet–lymphocyte score